TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06072612
Drug: Treatment of Physician's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
Study: NCT06017037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate tablets encapsulated to aid blinding. To take per oral once daily for 7-9 days
Study: NCT06362707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets that look identical to the fasudil tablets and will follow the same dosing schedule as participants receiving fasudil.
Study: NCT05878262
Drug: ibuprofen suppository
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the induction of anesthesia was performed, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg for the pre-emptive analgesia group children.
Study: NCT06080178
Drug: Plasma-lyte (static group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg
Study: NCT06080178
Drug: Norepinephrine (static group)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).
Study: NCT06080178
Drug: Plasma-lyte (dynamic group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmalyte will be administered intravenously:~(1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg.
Study: NCT05957471
Drug: Drug: BC3195 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC3195 via intravenous(IV).
Study: NCT06348290
Drug: JMKX001899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06348290
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT06080178
Drug: Norepinephrine (dynamic group)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg.
Study: NCT05224167
Drug: Melatonin 5 MG Sublingual Tablet
Normalized name: melatonin 5 MG Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg 12 hours and 2 hours prior to surgery
Study: NCT06096909
Drug: Cholesterol Absorption Inhibitor
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.
Study: NCT06096909
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.
Study: NCT06141356
Drug: [18F]Florbetazine ([18F]92)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer \[18F\]Florbetazine and will undergo a PET/CT scan.
Study: NCT06141356
Drug: [11C]PIB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer \[11C\]PIB and will undergo a PET/CT scan.
Study: NCT05300438
Drug: TSN084
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01076439
Drug: Saline Nasal Spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04448028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.
Study: NCT04880291
Drug: GFB-024
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody
Study: NCT04880291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT05439213
Drug: Adrenaline 0,33 Mg/mL Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: adrenaline dosage
Study: NCT05439213
Drug: Adrenaline 1 Mg/mL Solution for Injection
Normalized name: Adrenaline 1 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: adrenaline dosage
Study: NCT05126251
Drug: Tangningtongluo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangningtongluo Tablet is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome. The present study shows that Tangningtongluo Tablet have certain hypoglycemic effects in diabetic animal models and diabetic patients, and may improve insulin sensitivity in diabetic mice.It is speculated that the drug may be effective for prediabetes. (0.4g/tablet,Plate(12 pills/plate ×3 plates/box))
Study: NCT05020015
Drug: Chemotherapy Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine and cyclophosphamide as per standard of care.
Study: NCT05732103
Drug: CTX-712
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
Study: NCT06151509
Drug: Alpha-Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06151509
Drug: α-adrenergic receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05705349
Drug: DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
Study: NCT06370884
Drug: IMT
Normalized name: Imtack
Approvals — FDA: no, EMA: no, PMDA: no
Description: a feeding tube placed at the time of surgery and receive IMT solution on postoperative day 2-3 (at least 48 hours following IV antibiotics) with the subsequent removal of the feeding tube.
Study: NCT05181189
Drug: DAOIB+Omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.
Study: NCT05181189
Drug: DAOIB+Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05749432
Drug: Hemay181
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.
Study: NCT02614352
Drug: AG1502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05182840
Drug: Placebo to BI 690517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets
Study: NCT05022121
Drug: Medical Care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
Study: NCT04708236
Drug: ORTD-1 mid dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.
Study: NCT04744090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.
Study: NCT05796206
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous (IV) infusion of placebo will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.
Study: NCT04901689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05610280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen-matching placebo will be administered by SC injection.
Study: NCT06607263
Drug: Toothpaste
Normalized name: TOOTHPASTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: A commercially available fluoride toothpaste
Study: NCT04710043
Drug: BNT152
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT00248963
Drug: Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04710043
Drug: BNT153
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT04795336
Drug: Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg
Study: NCT05922800
Drug: Gamma-Oryzanol
Normalized name: gamma-oryzanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this group were given orally gamma-oryzanol tablets 20mg each time, three times a day, for 6 months.
Study: NCT04478734
Drug: Moderate doses of Thiamine y Biotin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine 600 mg every day + Biotin 150mg every day
Study: NCT05854498
Drug: TAS102
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35mg/m2 PO BID on days 1-5 and 15-19
Study: NCT00742833
Drug: KUC-7483
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00742833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04812262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug of DD01, administered in a 1mL volume for injection
Study: NCT05166837
Drug: STSA-1002 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05166837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05489952
Drug: iron sucrose and ferrous lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.
Study: NCT04784442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, tablet, once daily, for 12 weeks
Study: NCT05969847
Drug: CAPOX
Normalized name: Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Oxaliplatin,130mg/m2，ivgtt，d1,for 6 cycles. Drug: Capecitabine,1000mg/m2，po，bid，d1-14, for 6 cycles.
Study: NCT03235232
Drug: BREMEN eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
Study: NCT03235232
Drug: Combigan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
Study: NCT05509868
Drug: PBK_L1704 0.35mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive PBK_L1704 0.35mg/ml by PCA
Study: NCT05509868
Drug: PBK_L1704 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive PBK_L1704 0.5mg/ml by PCA
Study: NCT05509868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive placebo by PCA
Study: NCT04500847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg daily oral dose
Study: NCT06478381
Drug: L218CAR19
Approvals — FDA: no, EMA: no, PMDA: no
Description: L218CAR19 is intravenously administered at three dose levels.
Study: NCT04665089
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~* Pro-inflammatory cytokine (TNF alpha)~* Anti-inflammatory cytokine (IL-10)~* Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)
Study: NCT06140953
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional treatment will be taken in control group
Study: NCT04492488
Drug: MRG002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT05518578
Drug: SPN-817
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT05348278
Drug: Urea cream
Normalized name: Amino Acid-Urea Cream
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply 10% urea cream at both hands and feet twice daily
Study: NCT05127746
Drug: DA-5207 B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 patch once weekly
Study: NCT06215378
Drug: Antagonization of heparin with protamine sulfate
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: A systematic use at the end of procedure of Protamine Sulfate for antagonization of heparine.1 mg of protamine sulfate neutralizes approximately 100 heparin unit. To be administered in slow infusion (10 min) not exceeding 50mg of protamine sulfate to reverse 100% of the anti-IIa activity of heparin sodium. If the ACT is not back to the baseline value after the end of this infusion, additional doses of protamine should be performed depending on the ACT value to obtain complete antagonization of anti-IIa activity of heparin sodium
Study: NCT05327803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken orally QD
Study: NCT04965753
Drug: FHD-609
Approvals — FDA: no, EMA: no, PMDA: no
Description: FHD-609 as a single, intravenously administered agent given twice-weekly (BIW). Alternative dosing regimens may be evaluated.
Study: NCT06547554
Drug: Xeruborbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT06578078
Drug: Standard of care treatment (RAASi therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment (RAASi therapy) without use of sodium zirconium cyclosilicate
Study: NCT04825730
Drug: JOINTSTEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
Study: NCT05657574
Drug: D086
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, once daily, 8 weeks
Study: NCT05657574
Drug: Placebo (for D377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily, 8 weeks
Study: NCT05657574
Drug: Placebo (for CKD-331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily, 8 weeks
Study: NCT05657574
Drug: Placebo (for D086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily, 8 weeks
Study: NCT05983250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06286878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to use dapagliflozin or placebo in a double-blind way
Study: NCT04893915
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Lymphodepleting regimen
Study: NCT06650332
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin: 130 mg/m\\(\^2\\), IV, D1; Capecitabine: 1000 mg/m\\(\^2\\), oral (PO), twice daily, D1-14.
Study: NCT06650332
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m\\(\^2\\), IV, d1; Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1; 5-FU 400 mg/m\\(\^2\\), IV, d1, followed by 2400 mg/m\\(\^2\\), continuous intravenous infusion over 46 hours.
Study: NCT06333600
Drug: Saline spray
Normalized name: Saline Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05254977
Drug: Standard Preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any kind of intervention received to reduce adverse effects
Study: NCT05963022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04349826
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 20 mg/kg/day for 7 days
Study: NCT04349826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefixime-matched placebo for 7 days
Study: NCT05266729
Drug: Polyene Phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
Study: NCT05266729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection
Study: NCT06147856
Drug: mRNA-3210
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06054750
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)
Study: NCT05532293
Drug: MSP008-22
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro \& in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.
Study: NCT05069870
Drug: SKLB1028
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKLB1028, capsule, oral
Study: NCT06532240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An identical volume of 5% dextrose solution from the placebo drug bag will be administered to patients using the same protocol as intervention arm.
Study: NCT06231771
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage · Dosing of placebo is based on ulcer size. the volume will be samed as the experimental groups which is 2 ml per 1cm2 Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
Study: NCT03998852
Drug: Positron Emission Tomography (PET) with [18F]-FEOBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron Emission Tomography (PET) with \[18F\]-FEOBV
Study: NCT05867329
Drug: Intravenous Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug will be administered as 30mg twice daily during the first stage of treatment (if applicable) and through the second stage of treatment (if applicable). Prior to discharge a patient will be switched from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
Study: NCT05296369
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid was added during the period prior to concurrent chemoradiotherapy
Study: NCT06043544
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
Study: NCT05563155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet given on day 1 after surgery.
Study: NCT06056323
Drug: HB0045 Drug Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.
Study: NCT06099080
Drug: SM-020 gel 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study.
Study: NCT05478031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~Placebo: placebo oral suspension bid for 28 days and during the 14-days run-in phase